41 related articles for article (PubMed ID: 21330048)
21. Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.
Rosen RC; Seftel AD
Int J Impot Res; 2008 Dec; 20 Suppl 3():S27-32. PubMed ID: 19002122
[TBL] [Abstract][Full Text] [Related]
22. Treatment of lower urinary tract symptoms: agents for intraprostatic injection.
Andersson KE
Scand J Urol; 2013 Apr; 47(2):83-90. PubMed ID: 23281591
[TBL] [Abstract][Full Text] [Related]
23. Management of benign prostatic hyperplasia by family physicians.
Toguri A; Barkin J
Can J Urol; 2010 Feb; 17 Suppl 1():26-34. PubMed ID: 20170598
[TBL] [Abstract][Full Text] [Related]
24. An algorithm for medical management in male lower urinary tract symptoms.
Djavan B; Margreiter M; Dianat SS
Curr Opin Urol; 2011 Jan; 21(1):5-12. PubMed ID: 21045704
[TBL] [Abstract][Full Text] [Related]
25. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.
Carbone DJ; Hodges S
Int J Impot Res; 2003 Aug; 15(4):299-306. PubMed ID: 12934061
[TBL] [Abstract][Full Text] [Related]
26. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
[TBL] [Abstract][Full Text] [Related]
27. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options?
Robert G; Descazeaud A; de la Taille A
Curr Opin Urol; 2011 Jan; 21(1):42-8. PubMed ID: 21045706
[TBL] [Abstract][Full Text] [Related]
28. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
29. Plant extracts: sense or nonsense?
Madersbacher S; Berger I; Ponholzer A; Marszalek M
Curr Opin Urol; 2008 Jan; 18(1):16-20. PubMed ID: 18090484
[TBL] [Abstract][Full Text] [Related]
30. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms.
Parsons JK
Curr Opin Urol; 2011 Jan; 21(1):1-4. PubMed ID: 21045705
[TBL] [Abstract][Full Text] [Related]
31. [Experience in administration of cholinolytics in the treatment of patients with prostatic adenoma and symptoms of the lower urinary tract].
Pushkar' DIu; Rasner PI
Urologiia; 2011; (2):80-5. PubMed ID: 21815465
[No Abstract] [Full Text] [Related]
32. New intraprostatic injectables and prostatic urethral lift for male LUTS.
Magistro G; Stief CG; Gratzke C
Nat Rev Urol; 2015 Aug; 12(8):461-71. PubMed ID: 26195444
[TBL] [Abstract][Full Text] [Related]
33. [THE MODERN VIEW OF CONSERVATIVE THERAPY OF LOWER URINARY TRACT SYMPTOMS IN MEN].
Ergakov DV; Martov AG
Urologiia; 2015; (5):97-100, 102-3. PubMed ID: 26859950
[TBL] [Abstract][Full Text] [Related]
34. Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel.
Golzarian J; Antunes AA; Bilhim T; Carnevale FC; Konety B; McVary KT; Parsons JK; Pisco JM; Siegel DN; Spies J; Wasserman N; Gowda N; Ahrar K
J Vasc Interv Radiol; 2014 May; 25(5):665-74. PubMed ID: 24560898
[No Abstract] [Full Text] [Related]
35. Investigational procedures in benign prostatic hypertrophy.
Acquaye J; Borofsky MS
Curr Opin Urol; 2018 May; 28(3):315-321. PubMed ID: 29528973
[TBL] [Abstract][Full Text] [Related]
36. The use of voiding studies (flowmetry and urodynamics) in the assessment and follow-up of patients.
Tubaro A
Curr Opin Urol; 1999 Jan; 9(1):15-20. PubMed ID: 10726067
[TBL] [Abstract][Full Text] [Related]
37. Intraprostatic injection therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Chapple C
Eur Urol; 2011 May; 59(5):755-6. PubMed ID: 21330048
[No Abstract] [Full Text] [Related]
38. Botulinum neurotoxin A for male lower urinary tract symptoms.
Chartier-Kastler E; Mehnert U; Denys P; Giuliano F
Curr Opin Urol; 2011 Jan; 21(1):13-21. PubMed ID: 21099691
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
40. [New developments in the diagnosis of benign prostatic hyperplasia].
Vaida M; Novac B; Gheorghiu V; Novac C
Rev Med Chir Soc Med Nat Iasi; 2006; 110(1):88-96. PubMed ID: 19292085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
